Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4403-4411

  Costello, R T ^a   Mallet, F ^a   Gaugler, B ^a   Sainty, D ^a   Arnoulet, C ^a   Gastaut, J A ^a   Olive, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD86 ANTIGEN; DAUNORUBICIN; FAS ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER; CELL TRANSFORMATION; CLINICAL ARTICLE; COLONY FORMING CELL; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; TUMOR CELL CULTURE; TUMOR RESISTANCE;

ACUTE DISEASE; ADP-RIBOSYL CYCLASE; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD38; ANTIGENS, CD58; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CELL DIFFERENTIATION; DAUNORUBICIN; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; FAS LIGAND PROTEIN; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; HLA-DR ANTIGENS; HUMANS; LEUKEMIA, MYELOID; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; RNA, MESSENGER; TUMOR STEM CELLS;

EID: 0034662606     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. The graft-versus-leukemia effect
2. + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation
3. HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells
4. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
5. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
6. -
7. + subpopulations
8. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells
9. Single adult human CD34+/lin-/CD38- progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells
10. - cells in early and late trilineage haematopoietic engraftment after autologous blood cell transplantation
11. Proposed revised criteria for the classification of acute myeloid leukemia
12. Metalloproteinase-mediated release of human Fas ligand
13. The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells
14. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
15. Human leukemia-derived dendritic cells: Ex-vivo development of specific antileukemic cytotoxicity
16. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
17. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry
18. In vitro resistance to 1-βD-arabinofuranosylcytosine, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukemia
19. Upregulation of B7 molecules by the Epstein-Barr virus enhances susceptibility to lysis by a human NK-like cell line
20. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells
21. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: Flow cytometric detection of apoptotic cells using APO2.7 monoclonal apoptosis
22. Flow cytometry assessment of three different methods for the measurement of in vitro apoptosis
23. Monitoring early cellular response in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody
24. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
25. Fas receptor (CD95)-mediated apoptosis in leukemic cells
26. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukemia cells
27. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of Fas (APO-1/CD95) receptor/ligand system
28. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: Possible correlation with sensitivity to chemotherapy
29. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias
30. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia
31. -) in acute myeloid leukaemia
32. Multidrug resistance in leukemias and its reversal
33. Drug retention, efflux, and resistance in tumor cells
34. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
35. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity
36. The clinical significance of Fas expression in leukemia: Questions and controversies
37. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/FasL interactions
38. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells
39. Human monocytic cells contain high levels of intracellular Fas ligand. Rapid release following cellular activation
40. Tumor expression of Fas ligand (CD95L) and the consequences
41. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
42. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
43. The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
44. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
45. + large granular lymphocyte leukemia
46. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis
47. Transducers of life and death: TNF receptor superfamily and associated proteins
48. Autocrine interleukin-1 β regulates both proliferation and apoptosis in EL4-6.1 thymoma cells
49. DNA damage and mutation in human cells exposed to nitric oxide in vitro
50. Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing
51. Fas and perforin pathways as major mechanisms of T-cell mediated cytotoxicity
52. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogeneic immune recognition
53. Alloantigen presenting function of normal human CD34+ hematopoietic cells
54. Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells
55. Co-stimulation of T-cell immune response: A potential role in tumor immunology
56. Tumor immunity as autoimmunity: Tumor antigens include normal self proteins which stimulate anergic peripheral T cells
57. The role of the CD28 receptor during T cell responses to antigen
58. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation
59. Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity
60. A newly discovered class of human hematopoietic cells with SCID-repopulating activity